This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Basil M. Rifkind, MD, FRCP; David J. Gordon, MD
Department of Health and Human Services Bethesda, Md

JAMA. 1989;262(22):3128.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.—

As pointed out in the original report of the Lipid Research Clinics Coronary Primary Prevention Trial results,¹ the total incidence of fatal and nonfatal malignant neoplasms was similar in the cholestyramine resin and placebo groups. These incidence rates were somewhat lower than overall US cancer rates for comparably aged men. However, when the many different categories of malignancies were examined, the combined incidence of cancers of the mouth, pharynx, gastrointestinal tract, and pancreas was somewhat greater (21 vs 11 cases) in the cholestyramine resin group than in the placebo group. This excess incidence of gastrointestinal tract cancers was offset by reduced incidence of other cancers, particularly of the lung and prostate. The small numbers and multiple categories precluded firm conclusions, although the observation of excess cancers in the organ system directly exposed to cholestyramine resin was a matter of concern, especially in view of animal experiments in . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?